Tag: renal denervation
Symplicity Spyral renal denervation system gains Japanese PDMA approval
Medtronic has announced i...
DeepQure advances clinical trials of its HyperQure extravascular renal denervation system
DeepQure has announce...
Boston Scientific to acquire renal denervation technology developer SoniVie
Boston Scientific has...
TCT 2024: Two-year SPYRAL HTN-ON MED show “consistent” effect of renal denervation
Medtronic has announc...
ESC hypertension guidelines stipulate conditions for renal denervation use
ESC guidelines on the man...
First patients treated in US GPS study of Paradise renal denervation system
The first patients in...
Study of TIVUS renal denervation system for hypertension treatment completes enrolment
The REDUCED-1 study, a US...
SCAI: First US renal denervation approvals “revolutionise” treatment of uncontrolled hypertension
The approval of two renal...
Medtronic’s Symplicity Spyral renal denervation system granted US FDA approval for hypertension treatment
Medtronic has announced a...
FDA panel split on risk and benefit of Symplicity Spyral renal denervation system
The US Food and Drug ...
FDA panel votes favourably on safety and efficacy of Paradise renal denervation system
The US Food and Drug Admi...
Sham-controlled trials prompt renal denervation hypertension guideline update
Latest research in th...
ESH guidelines represent a “significant milestone” for hypertension management
ReCor Medical and its...
Patient advocacy group says ESH guideline change will improve access to renal denervation
Citizens of Europe at ris...
New arterial hypertension guidelines update recommendations on the use of renal denervation
New and expanded guidelin...
Blood pressure successfully cut in RADIANCE II ultrasound renal denervation trial
A new trial of endova...
ReCor appoints Lara Barghout to lead commercialisation of Paradise renal denervation system
ReCor Medical and its...
Ultrasound renal denervation meets primary efficacy endpoint in RADIANCE II study
ReCor Medical and Otsuka ...
New consensus statement will take into account latest clinical trial evidence on renal denervation
A new consensus stat...
EuroPCR 2022: Sham controlled trials have “revitalised” interest in renal denervation
“Renal denervation h...
ACC.22: Three-year data show “durable blood pressure reductions” through renal denervation
Long-term data from the f...
TCT 2021: Randomised trials show “consistent” reduction in blood pressure through renal denervation
Randomised placebo-contro...
TCT 2021: Six-month RADIANCE-HTN TRIO results “open a window” for renal denervation
Six-month outcomes fr...
TCT 2021: Medtronic unveils data on hypertension treatment preferences, launches SPYRAL AFFIRM study
Medtronic has announced f...
ReCor Medical’s Paradise ultrasound renal denervation system used in first German cases
ReCor Medical has announc...
Renal denervation: The most advanced and efficacious interventional approach to treat hypertension
Following the release...
ESH position paper highlights renal denervation as a third option for hypertension management
European Society of Hyper...
Renal denervation still holds strong potential as a therapy for hypertension
Although renal denervatio...
EuroPCR 2019: Renal denervation linked to reduction in subclinical atrial fibrillation
Data presented at Eur...
RADIANCE SOLO HTN finds greater blood pressure drop after renal denervation
Six-month "on-medication"...
EuroPCR 2018: Positive data for renal denervation reignites interest in field
After two studies ind...
From SYMPLICITY HTN-1 to SPYRAL HTN-OFF MED: The story of renal denervation
It is now almost a de...
ESC 2017: SPYRAL HTN-OFF MED provides “proof of principle” that renal denervation works
Results from SPYRAL H...
Renal denervation devices are alternatives to drug therapy, Technavio reports
Analysts from Technavio h...
